Trends in the use of second trimester maternal serum screening from 1991 to 2003

Genetics in Medicine

Volumn 7, Issue 5, 2005, Pages 328-331

  Benn, Peter A ^a   Fang, Min ^a   Egan, James F X ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Down syndrome; Prenatal; Screening; Trimester; Utilization

Indexed keywords

ADULT; AMNIOCENTESIS; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY DIAGNOSIS; MALE; METHODOLOGY; PRENATAL DIAGNOSIS; REVIEW; SCREENING TEST; SECOND TRIMESTER PREGNANCY; STATISTICAL SIGNIFICANCE; ULTRASOUND; UNITED STATES;

BIOLOGICAL MARKERS; CONNECTICUT; DOWN SYNDROME; FEMALE; HUMANS; MATERNAL AGE; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 20444507555     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000162875.36352.A9     Document Type: Review

References (30)

1. Hook EB. Prevalence, risks and recurrence. In: Brock DJH, Rodeck CH, Ferguson-Smith MA, editors. Prenatal Diagnosis and Screening. Edinburgh: Churchill Livingston, 1992.
2. Driscoll DA for the Professional Practice and Guidelines Committee. Second trimester maternal serum screening for open neural tube defects and aneuploidy. Genet Med 2004;6:540-541.
3. American College of Obstetricians and Gynecologists. ACOG Pract Bull. May 2001; 27.
4. Cuckle H. Established markers in second trimester maternal serum. Early Hum Develop 1996;47:S27-S29.
5. Benn PA, Fang M, Egan JFX, Horne D, Collins R. Incorporation of Inhibin-A in second-trimester screening for Down syndrome. Obstet Gynecol 2003;101:451-454.
6. Wald NJ, Huttley WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test. Lancet 2003;361:835-836.
7. Shipp TD, Benacerraf BR. Second trimester ultrasound screening for chromosomal abnormalities. Prenat Diagn 2002;22:296-307.
8. Bindra, Heath V, Liao A, Spencer K, Nicolaides KH. One-stop clinic for assessment for risk for trisomy 21 at 11-14 weeks: a prospective study of 15,030 pregnancies. Ultrasound Obstet Gynecol 2002;20:219-225.
9. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K et al; First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003; 349:1405-1413.
10. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999;341:461-467.
11. Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. Contingent screening is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 24:762-766.
12. Ferguson-Smith M, Aitken D, Arbuzova S, Benn P, Canick J, Cuckle H et al. Down syndrome screening: a position statement from the scientific committee of the international Down syndrome screening group, 2004. Available at: http://www.leeds.ac.uk/idssg/position%20statement.htm. Accessed January 10, 2005.
13. Benn PA. Preliminary evidence for associations between second trimester human chorionic gonadotropin and unconjugated estriol levels with pregnancy outcome in Down syndrome pregnancies. Prenat Diagn 1998;18:319-324.
14. Bray I, Wright DE, Davies C, Hook EB. Joint estimation of Down syndrome risk and ascertainment rates: a meta-analysis of nine published data sets. Prenat Diagn 1998; 18:9-20.
15. Benn PA, Egan JFX. Survival of Down syndrome in utero. Prenat Diagn 2000;20: 432-439.
16. National Center for Health Statistics. Vital statistics of the United States: 1991-2001. Natality Data Set. Hyattsville, MD.
17. Benn PA, Egan JFX, Fang M, Smith-Bindman R. Changes in the utilization of prenatal diagnosis. Obstet Gynecol 2004;103:1255-1260.
18. Benn PA. Advances in prenatal screening for Down syndrome: I general principles and second trimester testing. Clinica Chimica Acta 2002;323:1-16.
19. Benn PA, Ying J, Beazoglou T, Egan JFX. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results. Prenat Diagn 2001;21:46-51.
20. Seeds JW. Diagnostic mid trimester amniocentesis: how safe? Am J Obstet Gynecol 2004;191:608-616.
21. Ferguson-Smith MA, Yates JRW. Maternal age specific rates for chromosome aberrations and factors influencing them: report of a collaborative European study on 52,965 amniocenteses. Prenat Diagn 1984;4S:5-44.
22. Egan JFX, Benn P, Borgida AF, Rodis JF, Campbell WA, Vintzileos AM. Efficacy of screening for Down syndrome in the United States from 1974 to 1997. Obstet Gynecol 2000;96:979-985.
23. Beazoglou T, Heffley D, Kyriopoulos J, Vintzileos A, Benn PA. Economic evaluation of prenatal screening for Down syndrome in the USA. Prenat Diagn 1998;18:1241-1252.
24. Egan JFX, Kaminsky LM, DeRoche ME, Barsoom MJ, Borgida AF, Benn PA. Antenatal Down syndrome screening in the U. S. in 2001: A survey of maternal-fetal medicine specialists. Am J Obstet Gynecol 2002;187:1230-1234.
25. Pinette MG, Egan JFX, Wax JR, Blackstone J, Cartin A, Benn PA. Combined sonographic and biochemical markers for Down syndrome screening. J Ultrasound Med 2003;22:1185-1190.
26. Haddow JE, Palomaki GE, Knight GJ, Canick JA. Prenatal Screening for Major Fetal disorders. The Foundation for Blood Research handbook, II: Screening for Down syndrome. Maine: Foundation for Blood Research, 1998.
27. Benn PA, Fang M, Egan JFX, Horne D, Collins R. Incorporation of Inhibin-A in second-trimester screening for Down syndrome: Reply to Hallahan et al. Obstet Gynecol 2003;102:413-414.
28. Chen J, Heffley D, Beazoglou T, Benn P. Utilization of amniocentesis by women screening positive for Down syndrome on the second-trimester triple test. Commun Genet 2000;3:24-30.
29. Rowley PT. Genetic screening: marvel or menace? Science 1984;225:138-144.
30. Benn PA. Improved antenatal screening for Down's syndrome. Lancet 2003;361: 794-795.